Clinical immunotoxicity of antirheumatic drugs

G. Bálint, P. Gergely

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Non-steroidal antiinflammatory drugs (NSAIDs), corticosteroids and disease modifying antirheumatic drugs are commonly used for the treatment of the inflammatory rheumatic diseases. In addition to their antiinflammatory effects, many of these drugs influence an otherwise impaired immune system, which may result clinically in decreased resistance to infection and/or increased incidence of malignancies, in stimulation of the immune response and autoimmune diseases, or in allergy or hypersensitivity. Only corticosteroids increase considerably the risk of infections, immunosuppressive agents - at the low doses used in rheumatology - do not have this effect. Although the data are conflicting, neoplasms, especially leukaemias and lymphomas seem to develop more frequently during immunosuppressive treatment. Methotrexate, most commonly used nowadays in the early stage of joint disease, does not seem to increase the risk of malignancies. Although several drugs may induce autoimmune diseases, d-penicillamine is the commonest inducer. NSAIDs have the greatest propensity to produce allergy or hypersensitivity, causing various cutaneous, renal, and bronchial symptoms, and rarely vasculitis. Methods for the measurement of their plasma concentrations are available for most of the drugs, although not routinely used. Clinical vigilance, regular check-ups and full knowledge of side effects are crucial in the diagnosis of drug-induced immunotoxicity, especially because the symptoms and signs of immunotoxicity may mimic the naturally occurring features of the underlying disease.

Original languageEnglish
JournalInflammation Research
Volume45
Issue numberSUPPL. 2
Publication statusPublished - 1996

Fingerprint

Antirheumatic Agents
Hypersensitivity
Pharmaceutical Preparations
Allergies
Anti-Inflammatory Agents
Immunosuppressive Agents
Autoimmune Diseases
Adrenal Cortex Hormones
Neoplasms
Penicillamine
Joint Diseases
Immune system
Immune System Diseases
Rheumatology
Vasculitis
Infection
Rheumatic Diseases
Methotrexate
Signs and Symptoms
Immune System

Keywords

  • Antirheumatic drug
  • Effect
  • Immunotoxicity adverse
  • Monitoring

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology (medical)
  • Immunology
  • Cell Biology

Cite this

Clinical immunotoxicity of antirheumatic drugs. / Bálint, G.; Gergely, P.

In: Inflammation Research, Vol. 45, No. SUPPL. 2, 1996.

Research output: Contribution to journalArticle

Bálint, G. ; Gergely, P. / Clinical immunotoxicity of antirheumatic drugs. In: Inflammation Research. 1996 ; Vol. 45, No. SUPPL. 2.
@article{db5fb04b7cd5480a8ca04f10e838d851,
title = "Clinical immunotoxicity of antirheumatic drugs",
abstract = "Non-steroidal antiinflammatory drugs (NSAIDs), corticosteroids and disease modifying antirheumatic drugs are commonly used for the treatment of the inflammatory rheumatic diseases. In addition to their antiinflammatory effects, many of these drugs influence an otherwise impaired immune system, which may result clinically in decreased resistance to infection and/or increased incidence of malignancies, in stimulation of the immune response and autoimmune diseases, or in allergy or hypersensitivity. Only corticosteroids increase considerably the risk of infections, immunosuppressive agents - at the low doses used in rheumatology - do not have this effect. Although the data are conflicting, neoplasms, especially leukaemias and lymphomas seem to develop more frequently during immunosuppressive treatment. Methotrexate, most commonly used nowadays in the early stage of joint disease, does not seem to increase the risk of malignancies. Although several drugs may induce autoimmune diseases, d-penicillamine is the commonest inducer. NSAIDs have the greatest propensity to produce allergy or hypersensitivity, causing various cutaneous, renal, and bronchial symptoms, and rarely vasculitis. Methods for the measurement of their plasma concentrations are available for most of the drugs, although not routinely used. Clinical vigilance, regular check-ups and full knowledge of side effects are crucial in the diagnosis of drug-induced immunotoxicity, especially because the symptoms and signs of immunotoxicity may mimic the naturally occurring features of the underlying disease.",
keywords = "Antirheumatic drug, Effect, Immunotoxicity adverse, Monitoring",
author = "G. B{\'a}lint and P. Gergely",
year = "1996",
language = "English",
volume = "45",
journal = "Inflammation Research",
issn = "1023-3830",
publisher = "Birkhauser Verlag Basel",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Clinical immunotoxicity of antirheumatic drugs

AU - Bálint, G.

AU - Gergely, P.

PY - 1996

Y1 - 1996

N2 - Non-steroidal antiinflammatory drugs (NSAIDs), corticosteroids and disease modifying antirheumatic drugs are commonly used for the treatment of the inflammatory rheumatic diseases. In addition to their antiinflammatory effects, many of these drugs influence an otherwise impaired immune system, which may result clinically in decreased resistance to infection and/or increased incidence of malignancies, in stimulation of the immune response and autoimmune diseases, or in allergy or hypersensitivity. Only corticosteroids increase considerably the risk of infections, immunosuppressive agents - at the low doses used in rheumatology - do not have this effect. Although the data are conflicting, neoplasms, especially leukaemias and lymphomas seem to develop more frequently during immunosuppressive treatment. Methotrexate, most commonly used nowadays in the early stage of joint disease, does not seem to increase the risk of malignancies. Although several drugs may induce autoimmune diseases, d-penicillamine is the commonest inducer. NSAIDs have the greatest propensity to produce allergy or hypersensitivity, causing various cutaneous, renal, and bronchial symptoms, and rarely vasculitis. Methods for the measurement of their plasma concentrations are available for most of the drugs, although not routinely used. Clinical vigilance, regular check-ups and full knowledge of side effects are crucial in the diagnosis of drug-induced immunotoxicity, especially because the symptoms and signs of immunotoxicity may mimic the naturally occurring features of the underlying disease.

AB - Non-steroidal antiinflammatory drugs (NSAIDs), corticosteroids and disease modifying antirheumatic drugs are commonly used for the treatment of the inflammatory rheumatic diseases. In addition to their antiinflammatory effects, many of these drugs influence an otherwise impaired immune system, which may result clinically in decreased resistance to infection and/or increased incidence of malignancies, in stimulation of the immune response and autoimmune diseases, or in allergy or hypersensitivity. Only corticosteroids increase considerably the risk of infections, immunosuppressive agents - at the low doses used in rheumatology - do not have this effect. Although the data are conflicting, neoplasms, especially leukaemias and lymphomas seem to develop more frequently during immunosuppressive treatment. Methotrexate, most commonly used nowadays in the early stage of joint disease, does not seem to increase the risk of malignancies. Although several drugs may induce autoimmune diseases, d-penicillamine is the commonest inducer. NSAIDs have the greatest propensity to produce allergy or hypersensitivity, causing various cutaneous, renal, and bronchial symptoms, and rarely vasculitis. Methods for the measurement of their plasma concentrations are available for most of the drugs, although not routinely used. Clinical vigilance, regular check-ups and full knowledge of side effects are crucial in the diagnosis of drug-induced immunotoxicity, especially because the symptoms and signs of immunotoxicity may mimic the naturally occurring features of the underlying disease.

KW - Antirheumatic drug

KW - Effect

KW - Immunotoxicity adverse

KW - Monitoring

UR - http://www.scopus.com/inward/record.url?scp=0030476917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030476917&partnerID=8YFLogxK

M3 - Article

VL - 45

JO - Inflammation Research

JF - Inflammation Research

SN - 1023-3830

IS - SUPPL. 2

ER -